

SUBJ ECT INDEX TO VOLUME 3

| | | | |
|---|---------|--|---------|
| ABC transporters | 199 | Brucellosis | 359 |
| and drug milk secretion | 203 | control of | 359 |
| effect of resistance in protozoans | 202 | role of chemical/biological factors in | 359 |
| in parasite resistance | 199 | Buccal adhesive patches | 325 |
| in veterinary drug research | 199 | evaluation of | 325 |
| <i>Acanthophyllum squarrosum</i> | 399 | physicochemical characterization of | 325 |
| total saponin from | 399 | propranolol hydrochloride in | 325 |
| Aceclofenac | 417 | Calcium silicate | 367 |
| from lecithin organogels | 417 | based floating granular delivery system of | |
| preformulation study of | 417 | ranitidine hydrochloride | 367 |
| topical delivery of | 417 | Cancer | 59 |
| ADME | 181 | inhalation gene therapy for | 59 |
| related profiling of | 181 | Cationic microparticles | 116 |
| Aerosol gene therapy | 58 | as delivery systems for DNA vaccines | 116 |
| anticancer applications of | 60 | Charged microparticles | 116 |
| toxicity of | 58 | as delivery systems for adjuvants | 117 |
| Anthelmintics | 200 | for antibody induction to adsorbed protein | |
| as ABC substrates | 203 | antigens | 116 |
| drug resistance to | 200 | for induction of cell mediated immunity | 116 |
| Anti-HIV agent | 157 | mechanism of action of | 118 |
| elastic liposomal formulation of | 157 | Chitosan hydrogel | 356 |
| HPLC assay of | 159 | safety of | 356 |
| mechanism of action of | 157 | CNS delivery systems | 219 |
| pharmacokinetic study of | 159,163 | effect of blood cerebrospinal fluid barrier in | 221 |
| preparation of formulations of | 158 | liposomes in | 222 |
| skin permeation study of | 158 | nanocarrier-based | 219 |
| sustained/targeted delivery of | 157 | polymeric nanoparticles in | 226 |
| synergistic effect of | 162 | role of blood brain barrier in | 220 |
| vesicle-skin interaction study of | 163 | solid lipid nanoparticles in | 227 |
| Antiseptic agents | 315 | CNS diseases | 220 |
| delivery form drug carrier | 317 | barriers to drug delivery for | 220 |
| delivery of | 315 | Colloidal carriers | 275 |
| formulations of | 317 | as drug delivery systems | 280 |
| remanence/sustained activity of | 317 | for nasal drug delivery | 275 |
| scrubbing/rubbing formulations of | 315 | liposomes as | 275,281 |
| tolerance of | 317 | micro/nanoparticles as | 275 |
| topical based | 315 | microspheres as | 282 |
| Artificial sun protection | 405 | physiological considerations of | 275 |
| AZT | 158 | Controlled porosity osmotic pump | 193 |
| into vesicle at saturated concentration | 158 | Cutaneous gene therapy | 17 |
| pharmacokinetic study of | 163 | Cyclosporine A | 343 |
| Bacterial invasin | 47 | determination of encapsulation efficiency of | 344 |
| function of | 47 | differential scanning calorimetry (DSC) of | 344 |
| implication for targeted oral gene delivery | 47 | effect of grades of PLGA on | 343 |
| mechanism of | 49 | <i>in vitro</i> release of | 344 |
| mediated gene delivery | 50 | infrared spectroscopy (IR) studies of | 344 |
| structure of | 47,48 | microspheres encapsulated with | 343 |
| Biological membranes | 187 | Cytokine-secreting cells | 130 |
| lipid composition of | 187 | detection of | 130 |
| Biphasic lipid vesicles | 89 | Dendrimers | 215 |
| <i>in vitro</i> gene delivery into human skin using | 89 | in ocular therapy | 215 |
| <i>Brucella</i> | 359 | DermaVir | 44,84 |
| and role of chemical/biological factors | 359 | as novel topical vaccine for HIV/AIDS | 44 |
| control of | 359 | characteristics of | 84 |
| entry/fate in macrophages | 360 | immunizations in infected <i>macaques</i> | 86 |
| events in encounter between gentamicin and | 360 | | |

| | | | |
|---|-------|--|-----|
| protein expression of | 86 | Glibenclamide | 243 |
| targeting dendritic cells with | 84 | drug release studies of | 247 |
| to draining lymph nodes | 85 | mechanism of enhanced rectal absorption of | 252 |
| DNA delivery | 11,17 | pharmacodynamics of | 249 |
| for vaccination | 17 | Glipizide | 333 |
| formulation design for topical | 18 | assessment of bioavailability of | 335 |
| microenhancer arrays for | 11 | <i>in vitro</i> release studies of | 335 |
| novel mechanical/physical methods for | 11 | transdermal delivery system for | 333 |
| of therapeutics through skin | 17 | Helminths | 202 |
| DNA encoding | 25 | and role of efflux transporters | 202 |
| for therapeutic proteins | 25 | Hydrophilic matrices | 373 |
| naked DNA in | 25 | drug/cyclodextrin solid systems in design of | 373 |
| DNA-lipid complex | 37 | strategy to modulate drug delivery rate of | 373 |
| DNA vaccine | 18,29 | Immune stimulating complexes (ISCOMs) | 382 |
| administration of | 18 | as adjuvant/carriers | 382 |
| mechanism of immune induction from non- invasively topically applied | 32 | mechanism of | 382 |
| non-invasive immunization on skin using | 29 | modulation of T cell response by | 383 |
| topical administration of | 24 | Immuno-stimulating complex | 389 |
| Domperidone | 307 | characterization of | 392 |
| dissolution of | 307 | preparation from purified fractions | 393 |
| micromeritic behavior of | 307 | Inhalation delivery | 58 |
| particle study of | 308 | of polyethyl-eneimine-based polyplex formulations | 58 |
| solubility study of | 308 | Inhalation gene therapy | 56 |
| stability study of | 308 | history of | 56 |
| wettability of | 307 | Injectable chitosan/IO ₄ - heparin hydrogel | 356 |
| Drug release | 299 | Innovative ophthalmic drug delivery systems | 215 |
| measurements in limited amounts of liquid | 299 | Insulin | 399 |
| suppository formulation study of | 299 | characterization of | 399 |
| Elastic liposomal formulations | 158 | isolation of | 399 |
| characterizations of | 158 | study of enhancing effects on nasal absorption of | 399 |
| Electrically-assisted gene delivery | 77 | Integrin receptors | 49 |
| sequence/time dependence of transfection efficiency of | 77 | IR spectroscopic behavior | 101 |
| to tumors in mice | 77 | effect of aprotic solvents on | 101 |
| Electroporation | 23 | effect of azone on | 107 |
| role in gene expression | 23 | effect of cyclodextrin on | 109 |
| Fibroblast growth factor-2 (FGF-2) | 351 | effect of ethanol on | 101 |
| controlled releases of | 351 | effect of fatty acids on | 103 |
| effect on angiogenesis | 351 | effect of lipid synthesis inhibitors on | 110 |
| effect on tumor growth | 351 | effect of propylene glycol on | 102 |
| effects on wound repair | 351 | effect of surfactants on | 109 |
| for therapeutic angiogenesis in hind limb ischemia | 356 | effect of terpenes on | 104 |
| from chitosan hydrogels | 351 | effect of vehicles on | 101 |
| incorporated photocrosslinked chitosan hydrogel for wound management | 354 | Lipoplex gene delivery | 56 |
| Flurbiprofen | 193 | Liposomes | 379 |
| controlled porosity osmotic pump for delivery of | 193 | as adjuvant/carriers | 380 |
| β-Galactosidase enzyme | 67 | mechanism of action of | 380 |
| microneedle mediated delivery of | 67 | related particles | 381 |
| Gene delivery | 89 | Macromolecules | 65 |
| Gentamicin | 361 | microneedle-mediated delivery of | 68 |
| bioavailability of | 361 | minimally invasive cutaneous delivery of | 65 |
| drug delivery systems of | 361 | <i>via</i> microneedles | 65 |
| | | Melatonin | 255 |
| | | as pineal hormone | 255 |

| | | | |
|---|---------|--|-----|
| dissolution studies of | 256 | polymeric nanoparticles in | 226 |
| in model aqueous gastrointestinal | | solid lipid nanoparticles in | 227 |
| environments | 255 | Nanoparticles | 69 |
| solubilization studies of | 255 | microneedle mediated delivery of | 69 |
| Microemulsion | 167,267 | Nasal cavity | 275 |
| advantages of | 169 | anatomy of | 275 |
| application as drug delivery system | 174 | drug absorption through | 276 |
| applications of | 271 | Nasal delivery | 275 |
| as artificial blood substitute | 271 | barriers to nasal absorption in | 278 |
| as drug delivery systems | 167 | drug delivery to brain <i>via</i> | 280 |
| as microreactors for food application | 272 | of vaccines | 283 |
| as models for biological membranes | 271 | Non-CpG ODN | 131 |
| as oral solid dosage form | 268 | assessment of immunomodulatory effects of | 131 |
| buccal delivery of | 271 | Non-invasive administration | 3 |
| characterisation of | 173 | biological methods of | 11 |
| delivery routes for | 267 | chemical methods to | 5 |
| delivery through skin | 268 | femtosecond laser irradiation for | 12 |
| difference from emulsion | 169 | magnetofection for | 12 |
| electron microscopy for | 173 | mechanical methods of | 8 |
| for oral delivery | 175 | novel methods for | 3 |
| for parenteral/pulmonary/ocular/nasal/vaginal | | of DNA therapeutics | 3 |
| delivery | 176 | of vaccines | 3 |
| for topical delivery | 174 | physical methods of | 10 |
| formulation consideration of | 169 | sonoporation for | 12 |
| in aerosol form | 271 | using aqueous solution | 6 |
| intravaginal administration of | 270 | using bacterial ghosts | 11 |
| nasal delivery of | 271 | using bacterial vectors | 11 |
| ocular delivery of | 270 | using cationic lipids | 6 |
| oral delivery of | 267 | using electroporation | 10 |
| parenteral delivery of | 270 | using gene gun | 9 |
| periodontal delivery of | 271 | using liquid jet injection | 9 |
| phase diagram of | 172 | using microparticles | 7 |
| role of co-surfactant on | 171 | using mucoadhesive particulates/gels | 7 |
| role of oils on | 172 | using nanoparticles | 7 |
| role of surfactant on | 169 | using nebulizers | 10 |
| role of surfactant-co-surfactant ratio on | 172 | using polymers | 6 |
| role of temperature on | 172 | Non-invasive immunization | 30 |
| scattering method to | 173 | onto skin | 30 |
| solubility studies of | 169 | onto skin with DNA vaccine | 31 |
| storage stability of | 174 | Non-invasive pulmonary gene therapy | 55 |
| structure of | 167 | advances in | 55 |
| theories for formation of | 169 | combination of inhalation therapies for | 61 |
| Microemulsion based drug delivery system | 267 | Ocular drug delivery | 207 |
| applications of | 267 | advanced | 208 |
| Microneedle-mediated gene expression | 72 | contact lenses in | 210 |
| in excised human skin | 72 | corneal shield in | 210 |
| Microparticles | 115 | effect of temperature/pH induced gelation on | 210 |
| as adjuvants | 115 | iontophoresis in | 215 |
| mucosal immunization with | 117 | lyophilisate carrier system in | 213 |
| Micropelletization technique | 307 | microparticles in | 214 |
| Mucin | 243 | nanoparticles in | 214 |
| as release enhancer | 243 | ocular inserts in | 208 |
| evaluation of | 243 | of eye drops | 207 |
| for rectal delivery of glibenclamide | 243 | of ocular ointments/gels | 208 |
| Mucoadhesive dosage forms | 212 | penetration enhancers in | 213 |
| Nanocarrier-based delivery | 222 | role of ion activated gelation in | 211 |
| in CNS | 222 | role of liposomes in | 211 |
| liposomes in | 222 | role of niosomes in | 212 |

| | | | |
|---|-----|---|---------|
| role of vesicular systems in | 211 | RNA interference/siRNA | 147 |
| sol to gel systems as | 210 | cellular uptake of | 148 |
| submicron emulsions in | 214 | delivery strategies for | 147 |
| use of hyaluronic acid in | 212 | <i>in vitro</i> delivery strategies of | 148 |
| Oral gene delivery | 50 | <i>in vivo</i> bio-distribution of | 151 |
| Organogel | 422 | <i>in vivo</i> delivery strategies of | 151 |
| effect of added water on properties of | 422 | <i>in vivo</i> electroporation of | 153 |
| Paclitaxel | 351 | intranasal delivery to lung | 153 |
| controlled releases of | 351 | intraocular delivery of | 152 |
| effect on angiogenesis | 351 | intra-tumoural delivery of | 152 |
| effect on tumor growth | 351 | local delivery of | 152 |
| effects on wound repair | 351 | local delivery to central nervous system of | 153 |
| from chitosan hydrogels | 351 | mediated gene silencing | 147 |
| incorporated photocrosslinked chitosan | | physical methods for | 148 |
| hydrogel for tumor treatment | 353 | protein based delivery system for | 150 |
| Paclitaxel loaded chitosan films | 287 | role of bio-degradable polymers in | 149 |
| after implantation in mice | 287 | role of calcium co-precipitation in | 149 |
| <i>ev vivo</i> characterization of | 287 | role of cationic liposomes in | 149 |
| Particulate systems | 379 | role of cell penetrating peptides in | 150 |
| as adjuvants | 379 | role of polymers/dendrimers in | 149 |
| as carriers for peptide/protein antigens | 379 | systemic delivery of | 151 |
| Particulate vaccine delivery systems | 385 | Robust HT-assay | 181 |
| Penetration enhancers | 233 | for determination of lipophilicity | 181 |
| Photocrosslinked chitosan hydrogel | 352 | for determination of serum albumin binding | 181 |
| as biological adhesive | 352 | Saponin | 389,400 |
| Plasmid DNA | 65 | characterization of | 389,400 |
| minimally invasive cutaneous delivery of | 65 | extraction of | 400 |
| <i>via</i> microneedles | 65 | from <i>Quillaja saponaria</i> Molina | 389 |
| Poly lactide-co-glycolide microparticles | 115 | <i>in vivo</i> animal studies of | 400 |
| with surface adsorbed antigens as vaccine | | isolation of | 389 |
| delivery systems | 115 | to form immuno stimulatory complexes | |
| Polymer-based particles | 383 | (ISCOMs) | 389 |
| as adjuvant/carries | 383 | Skin | 95 |
| mucosal immunization by | 384 | spectroscopic attributes of | 100 |
| parenteral immunization by | 383 | thermotropic attributes of | 96 |
| Polyplex formulations | 61 | thermotropic/spectroscopic behavior of | 95 |
| for cancer immunotherapy | 61 | Skin barrier | 37 |
| for genetic immunization | 61 | Stratum corneum (SC) | 95 |
| Polyplex gene delivery | 57 | Subcutaneous delivery system | 129 |
| Prodrugs | 213 | biphasic lipid vesicles as | 129 |
| Pulmonary tuberculosis | 121 | for CpG oligonucleotides | 129 |
| management of | 121 | for protein antigens | 129 |
| microparticulate delivery systems (MDS) for | 125 | Sun protection factor | 406 |
| particulate drug carriers for | 124 | inorganic sunscreens as | 407 |
| particulate/vesicular drug carriers in | 121 | organic sunscreens as | 407 |
| Ranitidine hydrochloride | 367 | organometallic complexes as | 410 |
| controlled release of | 367 | photoprotectants as | 407 |
| high performance liquid chromatography | | sunscreens as | 407 |
| (HPLC) analysis of | 369 | Sunscreens | 405 |
| <i>in vitro</i> release studies of | 369 | carrier systems of | 405 |
| <i>in vivo</i> studies of | 369 | Therapeutic | 3 |
| Ready to go assays | 184 | systemic/mucosal delivery of | 5 |
| reproducibility of | 184 | Thermotropic | 101 |
| Ready to go plates | 184 | effect of aprotic solvents on | 101 |
| upscaling of using 384 well | 184 | effect of azone on | 107 |
| Ready to go principle | 184 | effect of cyclodextrin on | 109 |
| Rectal delivery | 243 | effect of ethanol on | 101 |

| | | | |
|---|-----|---------------------------------------|-----|
| effect of fatty acids on | 103 | needleless jet injectors in | 234 |
| effect of lipid synthesis inhibitors on | 110 | sonophoresis in | 236 |
| effect of propylene glycol on | 102 | use of lipophilic analogs in | 234 |
| effect of surfactants on | 109 | TRANSIL [®] assay | 182 |
| effect of terpenes on | 104 | Ultraviolet radiation | 405 |
| effect of vehicles on | 101 | and sun protection factor (SPF) | 405 |
| Topical DermaVir vaccine | 83 | antioxidants against | 407 |
| targeting dendritic cells with | 83 | effects on human skin | 405 |
| Topical DNA vaccination | 37 | UV inactive compounds | 183 |
| effect of adjuvants on | 40 | HPLC/LC/MS for | 183 |
| effect of plasmid DNA penetration | 37 | Vaccine delivery systems | 140 |
| efficacy of | 43 | adjuvants in | 141 |
| mechanism of | 43 | microparticles in | 142 |
| microemulsion (nanoparticles) delivery system | | of DNA vaccines | 140 |
| for | 40 | Vaccine | 3 |
| Th1/Th2 response of | 41 | systemic/mucosal delivery of | 5 |
| with DNA/lipid based complex | 37 | Vaccine delivery | 137 |
| Transdermal technologies | 233 | in transcutaneous immunization | 139 |
| developments for | 233 | nasal route of | 139 |
| in physical enhancement methods | 233 | oral route of | 138 |
| iontophoresis in | 238 | routes of administration of | 138 |
| laser-induced stress waves (LISWs) in | 236 | Vesicular drug carriers | 122 |
| liposomes in | 237 | | |
| magnetophoresis in | 238 | | |
| microporation in | 234 | | |